References:

  1. Swanson D, Block R, Mousa SA. Omega-3 fatty acids EPA and DHA: health benefits throughout life. Adv Nutr. 2012;3(1):1–7. doi:10.3945/an.111.000893.
  2. Braarud HC, Markhus MW, Skotheim S, et al. Maternal DHA Status during Pregnancy Has a Positive Impact on Infant Problem Solving: A Norwegian Prospective Observation Study. Nutrients. 2018;10(5):529. Published 2018 Apr 24. doi:10.3390/nu10050529.
  3. Smith SL, Rouse CA. Docosahexaenoic acid and the preterm infant. Matern Health Neonatol Perinatol. 2017;3:22. Published 2017 Dec 12. doi:10.1186/s40748-017-0061-1.
  4. Yassine HN, Braskie MN, Mack WJ, et al. Association of Docosahexaenoic Acid Supplementation With Alzheimer Disease Stage in Apolipoprotein E ε4 Carriers: A Review. JAMA Neurol. 2017;74(3):339–347. doi:10.1001/jamaneurol.2016.4899.
  5. McNamara RK. Role of Omega-3 Fatty Acids in the Etiology, Treatment, and Prevention of Depression: Current Status and Future Directions. J Nutr Intermed Metab. 2016;5:96–106. doi:10.1016/j.jnim.2016.04.004.
  6. Cipolli C, Chiari G. [Effects of L-acetylcarnitine on mental deterioration in the aged: initial results]. Clin Ter 1990; 132:479-510.
  7. Tempesta E, Casella L, Pirrongelli C, Janiri L, Calvani M, Ancona L. L-acetylcarnitine in depressed elderly subjects. A cross-over study vs placebo. Drugs Exp Clin Res 1987; 13:417-23.
  8. Garzya G, Corallo D, Fiore A, Lecciso G, Petrelli G, Zotti C. Evaluation of the effects of L-acetylcarnitine on senile patients suffering from depression. Drugs Exp Clin Res 1990; 16:101-6.
  9. Sano M, Bell K, Cote L, et al. Double-blind parallel design pilot study of acetyl levocarnitine in patients with Alzheimer’s disease. Arch Neurol 1992; 49:1137-41.
  10. Spagnoli A, Lucca U, Menasce G, et al. Long-term acetyl-L-carnitine treatment in Alzheimer’s disease. Neurology 1991; 41:1726-32.
  11. Brooks JO, 3rd, Yesavage JA, Carta A, Bravi D. Acetyl L-carnitine slows decline in younger patients with Alzheimer’s disease: a reanalysis of a double-blind, placebo-controlled study using the trilinear approach. Int Psychogeriatr 1998; 10:193-203.
  12. Rai G, Wright G, Scott L, Beston B, Rest J, Exton-Smith AN. Double-blind, placebo-controlled study of acetyl-l-carnitine in patients with Alzheimer’s dementia. Curr Med Res Opin 1990; 11:638-47.
  13. Thal LJ, Carta A, Clarke WR, et al. A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer’s disease. Neurology 1996; 47:705-11.
  14. Maggioni, M., et al., Effects of phosphatidylserine therapy in geriatric patients with depressive disorders. Acta Psychiatr Scand, 1990. 81(3): p. 265-70. in Alzheimer’s Patients.
  15. Amaducci, L., et al., Use of phosphatidylserine in Alzheimer’s disease. Ann N Y Acad Sci, 1991. 640: p. 245-9.
  16. Amaducci, L., Phosphatidylserine in the treatment of Alzheimer’s disease: results of a multicenter study. Psychopharmacol Bull, 1988. 24(1): p. 130-4.
  17. Little A, Levy R, Chuaqui-Kidd P, Hand D. A double-blind, placebo controlled trial of high-dose lecithin in Alzheimer’s disease. J. Neurol Neurosurg Psychiatry 1985;4 8(8):736-42.